Cross John Harry III 4
4 · Sonnet BioTherapeutics Holdings, Inc. · Filed Dec 5, 2024
Insider Transaction Report
Form 4
Cross John Harry III
Chief Financial Officer
Transactions
- Award
Common Stock
2023-12-11−1,452→ 1,588 total
Footnotes (3)
- [F1]On December 11, 2023, the Reporting Person was granted 1,452 restricted stock units, which will be settled in shares of common stock, par value $0.0001. The restricted stock units vest as to 100% of the restricted stock units on January 1, 2025.
- [F2]Includes unvested restricted stock units.
- [F3]All amounts reflect the Issuer's 1:22 reverse stock split effective as of August 31, 2023 and 1:8 reverse stock split effective as of September 30, 2024.